Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
MDxHealth (R) : Avis de publication des résultats semestriels 2018

2018-08-10 globenewswire
Une conférence téléphonique pour les analystes et les investisseurs est prévue le 30 août 2018 à 15:00 CET
MDXH

0
MDxHealth (R) : MDxHealth: Déclaration de Transparence d'un Actionnaire

2018-08-10 globenewswire
IRVINE, CA, et HERSTAL (BELGIQUE) - le 7 août 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" ou la "Société"), a annoncé avoir reçu le 3 août 2018 la notification des participations significatives suivante conformément à la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et portant des dispositions diverses (la «Loi Belge relative à la Transparence»).
MDXH

0
MDxHealth (R): MDxHealth Shareholder Transparency Declaration

2018-08-10 globenewswire
HERSTAL, BELGIUM and IRVINE, CA - August 7, 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), announced that it received on August 3, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act").
MDXH

0
MDxHealth (R): MDxHealth kennisgeving publicatie halfjaarcijfers 2018

2018-08-10 globenewswire
HERSTAL, BELGIË en NIJMEGEN, NEDERLAND - 10 augustus 2018 - MDxHealth SA, of de "Onderneming", zal de resultaten over het halfjaar afgesloten op 30 juni 2018 bekendmaken op donderdag 30 augustus 2018.
MDXH

0
MDxHealth Transparantieverklaring voor aandeelhouders

2018-08-07 globenewswire
HERSTAL, BELGIË en IRVINE, CA - 7 augustus 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" of de "Onderneming"), meldt dat het op 3 augustus 2018 een melding ontving overeenkomstig de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten, waarvan aandelen zijn toegelaten tot de handel op diverse bepalingen (de "Belgische Transparantiewet").
MDXH

0
MDxHealth (R): MDxHealth Shareholder Transparency Declaration

2018-08-07 globenewswire
HERSTAL, BELGIUM and IRVINE, CA - August 7, 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), announced that it received on August 3, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act").
MDXH

0
MDxHealth (R) : MDxHealth: Déclaration de Transparence d'un Actionnaire

2018-08-07 globenewswire
IRVINE, CA, et HERSTAL (BELGIQUE) - le 7 août 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" ou la "Société"), a annoncé avoir reçu le 3 août 2018 la notification des participations significatives suivante conformément à la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et portant des dispositions diverses (la «Loi Belge relative à la Transparence»).
MDXH

0
MDxHealth (R): SelectMDx-studie toont kosteneffectiviteit aan in Amerikaanse Gezondheidszorg

2018-07-31 globenewswire
Studie-data gepubliceerd in Journal of Urology schatten de jaarlijkse potentiële kostenbesparingen voor het Amerikaanse gezondheidszorgsysteem op $500 miljoen HERSTAL, BELGIË en NIJMEGEN, NEDERLAND, 31 July 2018 - MDxHealth SA ('MDxHealth', of 'de Onderneming'), (Euronext Brussel: MDXH.BR), mondiaal leidend in moleculaire diagnostiek voor urologische kankers, meldt de publicatie in The Journal of Urology van een studie die de kosteneffectiviteit van SelectMDx® voor prostaatkanker valideert, de niet-invasieve 'vloeibare biopsie' test die helpt bij het identificeren van patiënten met een verhoogd risico op agressieve prostaatkanker.
MDXH

0
MDxHealth (R) : Une étude démontre la rentabilité du test SelectMDx au sein du système de soins de santé américain

2018-07-31 globenewswire
COMMUNIQUÉ DE PRESSE INFORMATIONS RÉGLEMENTÉES Les données publiées dans la revue Journal of Urology indiquent que le système des soins de santé américain pourrait, chaque année, économiser plus de 500 millions de dollars
MDXH

0
MDxHealth: SelectMDx Study Demonstrates Cost-effectiveness in US Healthcare System

2018-07-31 globenewswire
NEWS RELEASE REGULATED INFORMATION Data published in Journal of Urology reports over $500 million in potential annual cost savings for the US healthcare system
MDXH

0
MDxHealth (R): Medicare Establishes Final Positive Local Coverage Determination for Use of ConfirmMDx for Prostate Cancer

2018-07-23 globenewswire
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, July 23, 2018 - MDxHealth SA (Euronext: MDXH.BR), today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a positive final Local Coverage Determination (LCD) to expand Medicare coverage of the ConfirmMDx for Prostate Cancer test.
MDXH

0
MDxHealth (R): Medicare Establishes Final Positive Local Coverage Determination for Use of ConfirmMDx for Prostate Cancer

2018-07-23 globenewswire
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, July 23, 2018 - MDxHealth SA (Euronext: MDXH.BR), today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a positive final Local Coverage Determination (LCD) to expand Medicare coverage of the ConfirmMDx for Prostate Cancer test.
MDXH

0
MDxHealth (R) : MDxHealth reçoit une détermination de couverture locale finale positive de la part de Medicare pour l'utilisation de ConfirmMDx for Prostate Cancer

2018-07-23 globenewswire
IRVINE, CA, et HERSTAL, BELGIQUE - 07h00 CEST, 23 juillet 2018 - MDxHealth SA (Euronext : MDXH.BR), a annoncé aujourd'hui que Palmetto GBA, un sous-traitant administratif de Medicare (Medicare Administrative Contractor, MAC) qui évalue les technologies de diagnostic moléculaire, a émis une détermination de couverture locale (local coverage determination, LCD) finale positive, augmentant ainsi la portée de la couverture Medicare du test ConfirmMDx for Prostate Cancer.
MDXH

0
MDxHealth (R): Medicare Establishes Final Positive Local Coverage Determination for Use of ConfirmMDx for Prostate Cancer

2018-07-23 globenewswire
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, July 23, 2018 - MDxHealth SA (Euronext: MDXH.BR), today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a positive final Local Coverage Determination (LCD) to expand Medicare coverage of the ConfirmMDx for Prostate Cancer test.
MDXH

0
Le test SelectMDx de MDxHealth classe avec succès les hommes

2018-06-27 globenewswire
De nombreux résumés d'étude clinique de SelectMDx présentés au congrès mondial sur le cancer de la prostate de 2018 à Francfort, en Allemagne
MDXH

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...